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Hepatocellular Screening Guidelines and Bellevue’s High Risk Population 
Ramoncito David 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the world.1  
The prevalence of this fatal disease greatly varies among different nations, due to the fact that almost 
80% of cases are secondary to hepatitis B or C.2 
The implementation of an effective vaccine against the hepatitis B virus (HBV) has reduced the 
prevalence of HBV carriers in North America to 0.1-2%; however, hepatitis B remains a global public 
health problem due its high prevalence in Asia and Africa, where 10-20% of the general population are 
carriers.3 
Hepatitis C in the United States is more prevalent in urban areas with higher populations of         
immigrants and intravenous drug users.  Bellevue’s patient population is at high risk for hepatocellular 
carcinoma because of our many Asian, African, and IV-drug-using patients and our relatively high rates 
of hepatitis B and C. 
According to the American Association for the Study of Liver Diseases (AASLD), patients at high 
risk for developing HCC should be entered into a surveillance program that screens them at regular   
intervals to check for new lesions in the liver.  By examining current guidelines and looking at how they 
are applied at Bellevue, we can shed some light on the question of whether we are screening too many 
patients or too few. 
The updated AASLD guidelines published in 2010 state that high-risk groups should be screened 
with ultrasonography every 6 months.4 Ultrasound as a screening test for HCC has a sensitivity that 
ranges from 65% to 80% and a specificity greater than 90%.  The main disadvantage of this test is that it 
is operator-dependent; hence the wide range in sensitivity.5 In addition, lesions in the liver are more   
difficult to detect sonographically in obese and cirrhotic patients, further decreasing the sensitivity.  
However, due to its cost-effectiveness, safety, and efficacy, ultrasonography is the preferred HCC 
screening and surveillance modality. 
Alpha-fetoprotein (AFP) is a serum marker that can be elevated in patients with primary liver can-
cer.  The optimal threshold for elevated AFP levels in HCC screening tests was found to be 20 ng/mL, 
but even then a screening test employing this cut-off would have a sensitivity of only 60% and a positive 
predictive value of only 41.5% when the prevalence of HCC is assumed to be 5%, as seen in most liver 
clinics.6  Some institutions use a combination of ultrasonography and AFP levels for screening, which 
results in increased sensitivity at the cost of a higher false positive rate.7  However, screening with AFP 
alone is not recommended, since it was shown in the Hepatitis C Antiviral Long-term Treatment Against 
Cirrhosis (HALT-C) Trial to be ineffective.8  Interestingly, studies imply that AFP is even less sensitive 
for the diagnosis of HCC in African-Americans with cirrhosis due to hepatitis C.9 
Some have suggested triple-phase CT scanning or MRI as alternative imaging options, but their use 
has not been studied in non-biased populations where there has not already been suspicion for HCC.10 
Moreover, given that the suggested interval time for screening is 6 months, CT scanning would expose 
the patient to high levels of radiation.  Serial MRIs and triple-phase CTs would also accrue significant 
costs.  However, given the availability of resources at some institutions and the lack of contrast-
enhanced ultrasonography in the United States11, CT scanning may be the best option for screening since 
it has been shown to have high sensitivity for finding lesions and is not as user-dependent as              
ultrasonography.  At Bellevue, surveillance for HCC in at-risk patients is done by CT scan or MRI every 
6 months, which is typically the length of time it takes for tumor size to double. 
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Limiting screening to high-risk patients makes sense because of the potential harm involved:  false 
positives can lead to further unnecessary testing and IV contrast can harm patients with renal              
insufficiency.   The many risk factors for developing HCC include race, male gender, hepatitis B carrier 
state, chronic hepatitis C infection, hereditary hemochromatosis, cirrhosis, non-alcoholic fatty liver dis-
ease, diabetes, alpha-1-antitrypsin deficiency, exposure to environmental toxins (aflatoxin, contaminated 
drinking water), smoking, and alcohol abuse.12-15  For non-cirrhotic hepatitis B patients, the AASLD 
guidelines suggest screening all Asian males over the age of 40, Asian females over the age of 50,     
patients with a positive family history of HCC, and Africans over the age of 20, regardless of carrier sta-
tus or viral load.  They also recommend screening all patients with cirrhosis of any etiology.16 
Using the subset of Asian HBV carriers as a study group, we can look more closely at the impact 
that screening has on mortality.  A 2004 trial based in Shanghai, randomized 18,816 Chinese patients 
between the ages of 35 to 59 with chronic hepatitis B to an active surveillance group followed with an 
AFP level and ultrasound every 6 months or to an observation group to be followed for up to 20 years.  
After 5 years they found that mortality due to HCC was significantly lower in the surveillance group 
compared to the observation group (83 per 100,000 vs. 132 per 100,000, mortality rate ratio 0.63, 95% 
CI 0.41-0.98).17  The 37% decrease in mortality was attributed to detection of the lesions at an earlier 
stage in the surveillance group. The number needed to treat (NNT) for this sample was 2,041.  Since the 
treatment offered in the study was resection, it is important to note that in the setting of chronic hepatitis 
B, HCC may arise prior to the development of cirrhosis, thus improving the prognosis for non-cirrhotic 
patients undergoing resection. 
Given the demonstrated benefit of early detection of HCC through screening, it is important to ex-
amine whether we healthcare providers are using screening to its full potential.  Cost-effectiveness is 
one way to assess this, and it is generally accepted that surveillance is cost-effective in cirrhotics who 
have an expected annual incidence of HCC greater than 1.5% per year.  Since the incidence of HCC in 
cirrhotic liver disease of any etiology typically ranges from 3% to 8% per year, it is clear that screening 
for these high-risk groups is cost-effective and potentially life-saving, given the high mortality rate    
associated with HCC.18,19   
In terms of the actual costs of screening tests, one study performed a cost-utility analysis comparing 
the incremental costs of four of the most commonly used screening modalities vs. no screening: AFP 
level alone, abdominal ultrasound and AFP, abdominal triple-phase CT and AFP, and abdominal MRI 
and AFP.  Utilizing Medicare reimbursement data as a standard of cost, they found that screening with 
ultrasonography and AFP level had an incremental cost-utility ratio of $26,689 per quality-adjusted life 
year, while abdominal CT and AFP was associated with an incremental cost-utility ratio of $25,232 per 
quality-adjusted life year.  AFP alone is not a viable option due to lack of efficacy, and MRI with AFP 
had a significantly higher cost-utility ratio of $118,000 per quality-adjusted life year.20 According to this 
data, abdominal CT with AFP level appears to be the most cost-effective screening modality.  More  
inclusive criteria for screening with CT and AFP would inevitably result in a marginal increase in finan-
cial burden, with the incremental costs being dependent on the number of new patients meeting the re-
vised criteria. 
Before considering a change in the criteria for screening, it is important to evaluate how well the 
current guidelines work when implemented at a hospital with a high volume of at-risk patients.  Here at 
Bellevue we see many patients with chronic hepatitis B, most of whom are immigrants from China who 
likely acquired the viral infection by vertical transmission during birth.  These patients have had a longer 
course of infection compared to patients who acquired HBV at a later age.  They can develop HCC    
earlier in their lives, prior to reaching the age at which screening is recommended according to the 
AASLD guidelines.  When there is no family history and no clinical finding of cirrhosis prompting us to 
screen these patients, they are often not diagnosed unless the lesion is found incidentally or the disease 
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reaches an advanced stage and becomes symptomatic.  Ironically, these young patients with non-cirrhotic 
livers are also the ones who would benefit most from early detection and subsequent resection.          
Unfortunately, they are not usually screened since they do not meet the criteria under the current    
guidelines.  Thus it would be helpful to establish more sensitive criteria for identifying patients who are 
at higher risk for developing early onset hepatocellular carcinoma.  One study has shown that in young 
HBV patients, smoking and cirrhosis were significant risk factors for developing HCC.21 In order for 
clinicians to implement the tool of screening in a more cost-effective and efficacious manner, further 
studies need to be done to elucidate important risk factors such as those that can be incorporated into a 
targeted algorithm for screening that includes those patients at highest risk for developing HCC at a 
young age.  
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